Cancer Immunology Reserch

Cancer Immunol Res. 2026 Sep 21:OF1-OF13. doi: 10.1158/2326-6066.CIR-26-0295. Online ahead of print. ABSTRACT Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non-small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently … Read more

Cancer Immunol Res. 2026 Sep 21. doi: 10.1158/2326-6066.CIR-26-0401. Online ahead of print. ABSTRACT Cell motility, characterized by random walk and exploratory search movement, enables effector CD8+ T cells to search for sparse antigen-specific cancer targets within a tumor. This is of special relevance for treatment of solid cancers with adoptive T-cell receptor (TCR) T-cell therapy, … Read more

Cancer Immunol Res. 2026 Sep 18. doi: 10.1158/2326-6066.CIR-25-1401. Online ahead of print. ABSTRACT Histone lactylation is an epigenetic modification that connects lactate metabolism with protein function. Our study identified lactate enhances the protein lactylation level not only in Myeloid-derived suppressor cells (MDSCs) of tumor-bearing mice, but also in the tumor tissues of lung cancer patients. … Read more

Cancer Immunol Res. 2026 Sep 17. doi: 10.1158/2326-6066.CIR-26-0236. Online ahead of print. ABSTRACT Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free … Read more

Cancer Immunol Res. 2026 Sep 15. doi: 10.1158/2326-6066.CIR-25-1567. Online ahead of print. ABSTRACT Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer … Read more

Cancer Immunol Res. 2026 Sep 11. doi: 10.1158/2326-6066.CIR-26-0213. Online ahead of print. ABSTRACT Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci impacts the tumor immune microenvironment and its association with resistance. We investigated the immune … Read more

Cancer Immunol Res. 2026 Sep 11. doi: 10.1158/2326-6066.CIR-26-0293. Online ahead of print. ABSTRACT Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is effective for treating advanced melanoma but requires surgical tumor resection. Malignant pleural effusions (MPE) may provide a more accessible source of tumor-reactive T cells. Synchronously collected MPE, lung metastasis, and blood from a patient … Read more

Cancer Immunol Res. 2026 Sep 11. doi: 10.1158/2326-6066.CIR-26-0106. Online ahead of print. ABSTRACT The spatial arrangement of immune cells in the tumor microenvironment (TME) varies widely, from dispersed to clustered and tumor excluded to infiltrating. Multiplexed spatial profiling is an effective means of characterizing tumor-infiltrating lymphocytes (TILs) and immune complexes such as tertiary lymphoid structures … Read more

Cancer Immunol Res. 2026 Jun 2;14(6):899. doi: 10.1158/2326-6066.CIR-14-6-WWR. NO ABSTRACT PMID:42726086 | DOI:10.1158/2326-6066.CIR-14-6-WWR

Cancer Immunol Res. 2026 Sep 9. doi: 10.1158/2326-6066.CIR-26-0070. Online ahead of print. ABSTRACT Myeloid checkpoint blockade as monotherapy often yields limited benefit, suggesting that multiple inhibitory pathways cooperatively sustain myeloid immunosuppression in the tumor microenvironment (TME). However, strategies to concurrently target multiple myeloid checkpoints remain challenging. Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble LILRA/B … Read more